Aktienanalyse zu Alkermes Plc (ALKS)ALKSAlkermes Plc

Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alkermes Plc (ALKS) is a good buy right now due to its strong revenue growth and favorable analyst outlook. The company reported a 27.5% increase in revenue year-over-year, reaching $888.9 million in the first half of 2026. Additionally, the stock has a median analyst price target of $59, which suggests a potential upside of 24.4% from the current price of $41.22. However, there is a risk of volatility as indicated by the current RSI of 56.78, which suggests it is nearing overbought territory. Overall, the positive growth trends and analyst confidence outweigh the risks, making it a solid investment opportunity for long-term investors.

12 analysts cover ALKS: 5 rate it Buy, 7 Hold and 0 Sell. The average price target is 46.20.